- Apr 21, 2023
- 1 min read

National Post: Rakovina preventing cancer cells from making DNA repairs they need to survive

Recent Posts

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research a

Rakovina Therapeutics Announces Strategic Pivot to AI

Using the platform powered by advanced AI algorithms, Rakovina can quickly analyze billions of molecular structures ..

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

The Company expects to submit the Type C meeting request by next week.